HAGHY vs. VRNA

Last updated Jun 13, 2026

HAGHY (Hensoldt AG) and VRNA (Verona Pharma plc) are both stocks. HAGHY operates in Aerospace & Defense (Industrials), while VRNA operates in Biotechnology (Healthcare). At a correlation of -0.02, they often move in opposite directions.

Performance

HAGHY vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Hensoldt AG (HAGHY) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

HAGHY

• 1D: -5.73%
• 1M: 0.63%
• YTD: 1.44%
• 6M: 2.37%
• 1Y: -19.30%
• 3Y*: 41.89%
• 5Y*: —
• 10Y*: —

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

HAGHY vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
HAGHY Hensoldt AG	1.44%	144.40%	31.10%	15.83%	-17.04%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	369.96%

Correlation

The correlation between HAGHY and VRNA is 0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.01
Correlation (3Y) Calculated over the trailing 3-year period	0.01
Correlation (All Time) Calculated using the full available price history since Mar 2, 2022	-0.02

Fundamentals

Market Cap HAGHY : $20.71B VRNA : $9.72B
EPS HAGHY : €0.08 VRNA : -$0.69
PS Ratio HAGHY : 3.80 VRNA : 57.97
PB Ratio HAGHY : 18.28 VRNA : 34.92
Total Revenue (TTM) HAGHY : €2.55B VRNA : $167.65M
Gross Profit (TTM) HAGHY : €535.68M VRNA : $159.52M
EBITDA (TTM) HAGHY : €413.05M VRNA : -$40.86M

Return for Risk

HAGHY vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HAGHY

HAGHY Risk / Return Rank: 28
HAGHY Sharpe Ratio Rank: 27
HAGHY Sortino Ratio Rank: 28
HAGHY Omega Ratio Rank: 28
HAGHY Calmar Ratio Rank: 27
HAGHY Martin Ratio Rank: 29

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HAGHY vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Hensoldt AG (HAGHY) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	HAGHY	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	-0.35	—	—
Sortino ratio: Return per unit of downside risk	-0.16	—	—
Omega ratio: Gain probability vs. loss probability	0.98	—	—
Calmar ratio: Return relative to maximum drawdown	-0.45	—	—
Martin ratio: Return relative to average drawdown	-0.74	—	—

Drawdowns

Drawdown Indicators

	HAGHY	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-42.91%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-42.91%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-42.91%	—	—
Current Drawdown Current decline from peak	-34.77%	—	—
Average Drawdown Average peak-to-trough decline	-20.42%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	26.00%	—	—

Volatility

Volatility by Period

	HAGHY	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.33%	—	—
Volatility (6M) Calculated over the trailing 6-month period	40.88%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	55.56%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	56.61%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	56.61%	—	—

Dividends

HAGHY vs. VRNA - Dividend Comparison

HAGHY's dividend yield for the trailing twelve months is around 0.74%, while VRNA has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022
HAGHY Hensoldt AG	0.74%	0.63%	1.20%	1.19%	1.10%
VRNA Verona Pharma plc	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

HAGHY vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Hensoldt AG and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

HAGHY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Hensoldt AG reported a gross profit of 69.00M and revenue of 496.00M. Therefore, the gross margin over that period was 13.9%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

HAGHY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Hensoldt AG reported an operating income of -4.00M and revenue of 496.00M, resulting in an operating margin of -0.8%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

HAGHY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Hensoldt AG reported a net income of -19.00M and revenue of 496.00M, resulting in a net margin of -3.8%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both HAGHY and VRNA in my portfolio?

HAGHY and VRNA have a correlation of 0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.